BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 32035259)

  • 1. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
    Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
    Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.
    Wang J; Ma W; Guo Q; Li Y; Hu Z; Zhu Z; Wang X; Zhao Y; Chai X; Tu P
    Int J Nanomedicine; 2016; 11():5851-5870. PubMed ID: 27853369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
    Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
    Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
    Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
    Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery.
    Hang C; Zou Y; Zhong Y; Zhong Z; Meng F
    Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid pH-responsive self-disintegrating nanoassemblies balance tumor accumulation and penetration for enhanced anti-breast cancer therapy.
    Li J; Wang Y; Xu C; Yu Q; Wang X; Xie H; Tian L; Qiu Y; Guo R; Lu Z; Li M; He Q
    Acta Biomater; 2021 Oct; 134():546-558. PubMed ID: 33882357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-layered cellulose nanocrystal system for CD44 receptor-positive tumor-targeted anticancer drug delivery.
    Seo JH; Lee SY; Hwang C; Yang M; Lee J; Lee SH; Cho HJ
    Int J Biol Macromol; 2020 Nov; 162():798-809. PubMed ID: 32585268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
    Haque ST; Islam RA; Gan SH; Chowdhury EH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
    [No Abstract]   [Full Text] [Related]  

  • 16. Doxorubicin-Loaded Carbon Dots Lipid-Coated Calcium Phosphate Nanoparticles for Visual Targeted Delivery and Therapy of Tumor.
    Zhang J; Zhang H; Jiang J; Cui N; Xue X; Wang T; Wang X; He Y; Wang D
    Int J Nanomedicine; 2020; 15():433-444. PubMed ID: 32021189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-targeted hyaluronic acid-b-poly (β-amino ester) pH-switchable polymersome for guided doxorubicin delivery to metastatic breast cancer.
    Borhaninia M; Zahiri M; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Int J Biol Macromol; 2023 Sep; 248():125882. PubMed ID: 37473882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid-modified yeast β-glucan particles delivering doxorubicin for treatment of breast cancer.
    He F; Xie C; Xu X
    Carbohydr Polym; 2023 Aug; 314():120907. PubMed ID: 37173014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid-coated single-walled carbon nanotubes loaded with doxorubicin for the treatment of breast cancer.
    Liu D; Zhang Q; Wang J; Fan L; Zhu W; Cai D
    Pharmazie; 2019 Feb; 74(2):83-90. PubMed ID: 30782256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies.
    Jamshidi Z; Sadat Zavvar T; Ramezani M; Alibolandi M; Hadizadeh F; Abnous K; Taghdisi SM
    Int J Pharm; 2022 Jul; 623():121892. PubMed ID: 35671850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.